Literature DB >> 4006362

Metabolite cumulation during chronic propafenone dosing in arrhythmia.

R E Kates, Y G Yee, R A Winkle.   

Abstract

The cumulation of propafenone and two of its metabolites, 5-hydroxypropafenone (5-OHP) and N-depropylpropafenone (NDPP), was examined in patients with frequent ventricular ectopy. After 2 weeks of propafenone therapy (300 mg twice a day), propafenone was discontinued and blood samples were drawn for 24 hours. The mean (+/- SD) steady-state concentrations of propafenone, 5-OHP, and NDPP were 1010 +/- 411, 174 +/- 113, and 179 +/- 93 ng/ml. The concentration ratios of 5-OHP/propafenone and NDPP/propafenone were 0.177 +/- 0.049 and 0.227 +/- 0.203. Plasma concentrations of 5-OHP and NDPP did not decay in a log-linear manner during the sampling period and thus estimates of their disappearance t1/2s were not possible. At 24 hours after propafenone dosing, concentrations of 5-OHP and NDPP were 63% +/- 37% and 50% +/- 21% of their mean steady-state levels. Our data indicate that these propafenone metabolites cumulate in the plasma during chronic oral propafenone therapy, and that their clinical role needs to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4006362     DOI: 10.1038/clpt.1985.97

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect.

Authors:  C Funck-Brentano; H K Kroemer; H Pavlou; R L Woosley; D M Roden
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

3.  Food increases the bioavailability of propafenone.

Authors:  J E Axelson; G L Chan; E B Kirsten; W D Mason; R C Lanman; C R Kerr
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

4.  Pharmacokinetics and pharmacodynamics of propafenone during acute and chronic administration.

Authors:  P Giani; M Landolina; V Giudici; C Bianchini; G Ferrario; S Marchi; E Riva; R Latini
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 5.  Propafenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.

Authors:  D W Harron; R N Brogden
Journal:  Drugs       Date:  1987-12       Impact factor: 9.546

6.  Drug interaction between propafenone and metoprolol.

Authors:  F Wagner; D Kalusche; D Trenk; E Jähnchen; H Roskamm
Journal:  Br J Clin Pharmacol       Date:  1987-08       Impact factor: 4.335

7.  Identification of propafenone metaboliser phenotype from plasma and urine excretion data.

Authors:  R Latini; M Belloni; R Bernasconi; E Cappiello; P Giani; M Landolina; D Leopaldi; J M Castel
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

8.  Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapy.

Authors:  A Capucci; G Boriani; B Marchesini; E Strocchi; L Tomasi; M Balducelli; L Frabetti; E Ambrosioni; B Magnani
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

9.  Nonlinear kinetics of propafenone metabolites in healthy man.

Authors:  S Vozeh; W Haefeli; H R Ha; J Vlcek; F Follath
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 10.  Propafenone in the treatment of cardiac arrhythmias. A risk-benefit appraisal.

Authors:  A Capucci; G Boriani
Journal:  Drug Saf       Date:  1995-01       Impact factor: 5.606

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.